What the FDA labels say about taking them together
Eflapegrastim and filgrastim
Eflapegrastim's FDA label of February 18, 2026 names filgrastim in its contraindications section; the filgrastim labels PlainMeds reads (4) do not name eflapegrastim. The eflapegrastim label: “Rolvedon is contraindicated in patients with a history of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim products.”
Check it at the source: the eflapegrastim FDA label on DailyMed (effective February 18, 2026); the filgrastim FDA label on DailyMed (effective July 23, 2026, Amgen, Inc).
What does the eflapegrastim label say about filgrastim?
Eflapegrastim label, contraindicationsCONTRAINDICATIONS Rolvedon is contraindicated in patients with a history of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim products.
Source: FDA drug label (Rolvedon), Spectrum Pharmaceuticals, Inc., effective February 18, 2026 (SPL set 6e436115-62e7-4729-aeb0-ff78ea685206), via openFDA; the full label on DailyMed
What does the filgrastim label say about eflapegrastim?
Filgrastim's label (effective July 23, 2026) and its 3 other brand-application labels do not name eflapegrastim in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (NEUPOGEN), Amgen, Inc, effective July 23, 2026 (SPL set 97cc73cc-b5b7-458a-a933-77b00523e193), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Eflapegrastim | Filgrastim | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $650.05 per mL 300 mcg/0.5 mL syringe |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once